This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dix, B. R. Articles by Braithwaite, A. W. Search for Related Content PubMed PubMed Citation Articles by Dix, B. R. Articles by Braithwaite, A. W.

Efficient Induction of Cell Death by Adenoviruses Requires Binding of E1B55k and p53¹

Cell Transformation Group, Department of Pathology, Dunedin School of Medicine, Dunedin, New Zealand 9001

The use of an E1b55k-deficient adenovirus, ONYX-015, to selectively target tumor cells containing a mutated p53 gene has produced promising results. However, recent reports have questioned the selectivity of this virus, showing that ONYX-015 can replicate in cells containing a wild-type p53 and that p53 may actually be required for cell death. To address these apparent contradictions in the literature, we infected a number of mutant and wild-type p53-containing cell lines with ONYX-015 and wild-type adenovirus and observed their death profiles up to 10 days postinfection. We demonstrate that two distinct cell death phenotypes exist, one of which is rapid and dependent on the presence of p53 and one of which is p53 independent. Using adenoviruses expressing E1b55k proteins deficient in their ability to bind p53, we show that formation of a complex between p53 and the adenoviral E1b55k protein is necessary for the activation of the rapid cell death pathway. In the absence of p53 or the absence of complex formation between p53 and E1b55k, cell death is delayed considerably. These data suggest three things: that the selectivity of killing appears to be dependent on the presence of the E1b55k/p53 complex; that viruses lacking E1b55k (such as ONYX-015) kill cells in a delayed manner independent of p53; and that binding of E1b55k to p53 does not merely serve to inactivate p53, but rather is required for the induction of rapid cell death. The components of this complex that lead to rapid cell death remain to be determined.

This article has been cited by other articles:

				D. Westphal, E. C. Ledgerwood, M. H. Hibma, S. B. Fleming, E. M. Whelan, and A. A. Mercer A Novel Bcl-2-Like Inhibitor of Apoptosis Is Encoded by the Parapoxvirus Orf Virus J. Virol., July 1, 2007; 81(13): 7178 - 7188. [Abstract] [Full Text] [PDF]

				R. Gonzalez, W. Huang, R. Finnen, C. Bragg, and S. J. Flint Adenovirus E1B 55-Kilodalton Protein Is Required for both Regulation of mRNA Export and Efficient Entry into the Late Phase of Infection in Normal Human Fibroblasts J. Virol., January 15, 2006; 80(2): 964 - 974. [Abstract] [Full Text] [PDF]

				S. Wadler, H. Kaufman, M. Horwitz, S. Morley, D. Kirn, R. Brown, S. Kaye, and D. Soutar The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma Clin. Cancer Res., April 1, 2005; 11(7): 2781 - 2782. [Full Text] [PDF]

				M. A. I. Abou El Hassan, I. van der Meulen-Muileman, S. Abbas, and F. A. E. Kruyt Conditionally Replicating Adenoviruses Kill Tumor Cells via a Basic Apoptotic Machinery-Independent Mechanism That Resembles Necrosis-Like Programmed Cell Death J. Virol., November 15, 2004; 78(22): 12243 - 12251. [Abstract] [Full Text] [PDF]

				B. Geoerger, G. Vassal, P. Opolon, C. M. F. Dirven, J. Morizet, L. Laudani, J. Grill, G. Giaccone, W. P. Vandertop, W. R. Gerritsen, et al. Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Ad{Delta}24-p53 against Human Malignant Glioma Cancer Res., August 15, 2004; 64(16): 5753 - 5759. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF]

				Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF]

				T. Wirth, L. Zender, B. Schulte, B. Mundt, R. Plentz, K. L. Rudolph, M. Manns, S. Kubicka, and F. Kuhnel A Telomerase-dependent Conditionally Replicating Adenovirus for Selective Treatment of Cancer Cancer Res., June 15, 2003; 63(12): 3181 - 3188. [Abstract] [Full Text] [PDF]

				S. J. Edwards, B. R. Dix, C. J. Myers, D. Dobson-Le, L. Huschtscha, M. Hibma, J. Royds, and A. W. Braithwaite Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes J. Virol., November 13, 2002; 76(24): 12483 - 12490. [Abstract] [Full Text] [PDF]

				V. W. van Beusechem, P. B. van den Doel, J. Grill, H. M. Pinedo, and W. R. Gerritsen Conditionally Replicative Adenovirus Expressing p53 Exhibits Enhanced Oncolytic Potency Cancer Res., November 1, 2002; 62(21): 6165 - 6171. [Abstract] [Full Text] [PDF]

				Y. S. Haviv, K. Takayama, J. N. Glasgow, J. L. Blackwell, M. Wang, X. Lei, and D. T. Curiel A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene Mol. Cancer Ther., March 1, 2002; 1(5): 321 - 328. [Abstract] [Full Text] [PDF]

				B. Geoerger, J. Grill, P. Opolon, J. Morizet, G. Aubert, M.-J. Terrier-Lacombe, B. Bressac de-Paillerets, M. Barrois, J. Feunteun, D. H. Kirn, et al. Oncolytic Activity of the E1B-55 kDa-deleted Adenovirus ONYX-015 Is Independent of Cellular p53 Status in Human Malignant Glioma Xenografts Cancer Res., February 1, 2002; 62(3): 764 - 772. [Abstract] [Full Text] [PDF]

				S. A. Vorburger and K. K. Hunt Adenoviral Gene Therapy Oncologist, February 1, 2002; 7(1): 46 - 59. [Abstract] [Full Text] [PDF]

				P. Koch, J. Gatfield, C. Lober, U. Hobom, C. Lenz-Stoppler, J. Roth, and M. Dobbelstein Efficient Replication of Adenovirus Despite the Overexpression of Active and Nondegradable p53 Cancer Res., August 1, 2001; 61(15): 5941 - 5947. [Abstract] [Full Text] [PDF]

				B. R. Dix, S. J. Edwards, and A. W. Braithwaite Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway? J. Virol., June 15, 2001; 75(12): 5443 - 5447. [Full Text]

				D. Wodarz Viruses as Antitumor Weapons: Defining Conditions for Tumor Remission Cancer Res., April 1, 2001; 61(8): 3501 - 3507. [Abstract] [Full Text]